BioMimetic Therapeutics, Inc. of Franklin, Tennessee, announced on February 10 that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of primary shares of its common stock. The company said Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC, will be acting as the co-lead manager and First Albany Capital, Inc. and AG Edwards & Sons, Inc. will be co-managers.

BioMimetic Therapeutics, Inc. is developing and commercializing bio-active drug-device combination products for the healing of musculoskeletal injuries and disease, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.

BioMimetic presented at the annual Southeastern BIO Investor Forum in 1999 and 2002.